Recombinant Human Protein Nov Homolog Protein (NOV), Active

Name: Recombinant Human Protein Nov Homolog Protein (NOV), Active
Brand: Beta LifeScience
SKU: BLC-05963P
Availability: InStock

Collections: Cytokines, Cytokines and growth factors, Growth factors and receptors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Protein Nov Homolog Protein (NOV), Active is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 95% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 1.0 μg/ml, corresponding to a specific activity of >1000 IU/mg.
Uniprotkb	P48745
Target Symbol	NOV
Synonyms	CCN family member 3; CCN3; IBP-9; IGF-binding protein 9; IGFBP-9; IGFBP9; Insulin-like growth factor-binding protein 9; Nephroblastoma overexpressed; Nephroblastoma overexpressed gene protein homolog; Nephroblastoma-overexpressed gene protein homolog; NOV; NOV_HUMAN; NovH; Protein NOV homolog
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Complete Sequence	M+QVAATQRCP PQCPGRCPAT PPTCAPGVRA VLDGCSCCLV CARQRGESCS DLEPCDESSG LYCDRSADPS NQTGICTAVE GDNCVFDGVI YRSGEKFQPS CKFQCTCRDG QIGCVPRCQL DVLLPEPNCP APRKVEVPGE CCEKWICGPD EEDSLGGLTL AAYRPEATLG VEVSDSSVNC IEQTTEWTAC SKSCGMGFST RVTNRNRQCE MLKQTRLCMV RPCEQEPEQP TDKKGKKCLR TKKSLKAIHL QFKNCTSLHT YKPRFCGVCS DGRCCTPHNT KTIQAEFQCS PGQIVKKPVM VIGTCTCHTN CPKNNEAFLQ ELELKTTRGK M
Expression Range	28-357aa
Protein Length	Full Length of Mature Protein
Mol. Weight	36.2 kDa
Research Area	Immunology
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 µm filtered PBS, pH 7.0
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival. Acts by binding to integrins or membrane receptors such as NOTCH1. Essential regulator of hematopoietic stem and progenitor cell function. Inhibits myogenic differentiation through the activation of Notch-signaling pathway. Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling. Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival. Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts. Involved in bone regeneration as a negative regulator. Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification. Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion. Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway. Contributes to the control and coordination of inflammatory processes in atherosclerosis. Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement.
Subcellular Location	Secreted. Cytoplasm. Cell junction, gap junction.
Protein Families	CCN family
Database References	HGNC: 7885 OMIM: 164958 KEGG: hsa:4856 STRING: 9606.ENSP00000259526 UniGene: Hs.235935
Tissue Specificity	Expressed in endiothelial cells (at protein level). Expressed in bone marrow, thymic cells and nephroblastoma. Increased expression in Wilms tumor of the stromal type.

Gene Functions References

A significant reduction of CCN3 expression was observed in lesioned skin compared to non-lesioned skin in vitiligo patients. PMID: 29998862
This is the first evidence of downregulation of TGFbeta1-mediated activation of a Smad1/5/8 signalling pathway by CCN3 in human podocytes and in any cell type. PMID: 29506624
NOV is a novel biomarker of the presence and severity of OSA and a potential marker of future cardiovascular and metabolic disease in OSA patients. PMID: 28862983
down-regulation of Lamin B1 and up-regulation of Nephroblastoma overexpressed (NOV) are at least partially responsible for the inhibitory effect of Huaier on the proliferative and invasive capacity of SKHEP-1 cells PMID: 27503760
NOV is down-regulated in CRC tumours which is associated with disease progression. PMID: 28412738
Taken together, our results suggest that palmitoylation by ZDHHC22 at C241 in the CCN3 TSP1 domain may be required for the secretion of CCN3. Aberrant palmitoylation induces intracellular accumulation of CCN3, inhibiting neuronal axon growth. PMID: 29287726
CCN3 (Nov) and CCN5 (WISP2) are novel substrates of MMP14. PMID: 27471094
Reduced levels of CCN1 and CCN3, as found in early-onset preeclampsia, could contribute to a shift from invasive to proliferative extravillous trophoblasts and may explain their shallow invasion properties in this disease. PMID: 26744771
our findings establish CCN3 as a pivotal regulator of androgen receptor (AR) signaling and prostate cancer progression and suggest a functional intersection between EZH2 and AR signaling in castration-resistant prostate cancer PMID: 27815387
The present study aimed to examine the clinical relevance of NOV along with CYR61 and CTGF in gastric cancer by analysing their transcript levels...the expression of NOV and CYR61 was increased in gastric cancer. The elevated expression of CYR61 was associated with poorer survival. NOV promoted proliferation and invasion of gastric cancer cells PMID: 27633176
Studies indicate that the CYR61 CTGF NOV matricellular proteins (CCN family of proteins) comprises the members CCN1, CCN2, CCN3, CCN4, CCN5 and CCN6 and have been identified in various types of cancer. PMID: 26498181
NOV expression was highly increased in biopsies of patients with tubulointerstitial nephritis. PMID: 26367310
Results revealed that NOV regulates the tumor growth of osteosarcoma cells through activation of the MAPK signaling pathway and promotes osteosarcoma cell migration in vitro. PMID: 26238193
our results argue that MZF-1 regulates the CTGF and NOV genes in the hematopoietic compartment, and may be involved in their respective functions in the stroma. PMID: 25899830
Overexpression of CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. PMID: 24721786
NOV may promote carcinogenesis via promotion of EMT and association with increased mTOR activity PMID: 24719190
over-expression of NOV in pancreatic cancer cells promoted cell proliferation and migration, while knock down the expression of NOV impaired the tumorigenecity of pancreatic cancer cells in vitro and in vivo PMID: 24258112
CCN3 may play an important role in cervical carcinogenesis and therefore may have potential as a biomarker for prognosis and as a therapeutic target in cervical cancer. PMID: 24431313
Our findings establish a tumor-suppressive role of NOV in prostate cancer PMID: 23318417
in obese humans and mice plasma NOV levels positively correlated with NOV expression in adipose tissue, and support a possible contribution of NOV to obesity-related inflammation. PMID: 23785511
These results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic beta-cells. PMID: 23705021
Presence of both forms of CCN3 is accompanied by a balance of trophoblast proliferation and migration/invasion properties, which are triggered by different signalling pathways. PMID: 23220688
CCN3 expression is higher in highly invasive PC3 cells. PMID: 23536580
Data suggest that urinary CCN3/CCN2 mRNA ratio may be a useful noninvasive biomarker for evaluating patients with nondiabetic chronic kidney disease (CKD) prior to renal biopsy. PMID: 23061738
Melanocytes remaining in perilesional vitiligo skin did not express CCN3. PMID: 22507556
results indicate that CCN3 enhances the migration of prostate cancer cells by increasing ICAM-1 expression through a signal transduction pathway that involves alphavbeta3 integrin, ILK, Akt and NF-kappaB PMID: 22345292
Provide evidence that CCN3 enhances BMP-4 expression and bone nodule formation in osteoblasts, and that the integrin receptor, ILK, p38, JNK, and AP-1 signaling pathways may be involved. PMID: 21898398
CCN3 protein regulates the decrease in Jeg3 cell numbers independent of its glycosylation status PMID: 21784733
CCN3 enhances the migration of chondrosarcoma cells by increasing MMP-13 expression through the alphavbeta3/alphavbeta5 integrin receptor, FAK, PI3K, Akt, p65, and NF-kappaB signal transduction pathway. PMID: 21344378
Data show reduced CCN3 levels in aRMS cells following small interfering RNA knockdown of PAX3-FKHR. PMID: 21423212
CCN3 regulates the differentiation of bone resident cells to create a resorptive environment that promotes the formation of osteolytic breast cancer metastases PMID: 21514448
Recombinant expression, purification, and functional characterisation of connective tissue growth factor and nephroblastoma-overexpressed protein PMID: 21209863
NOV acts through alphavbeta5 integrin to activate ILK and Akt, which in turn activates c-Jun and AP-1, resulting in the activations of COX-2 and contributing the migration of human osteosarcoma cells. PMID: 21145881
Only defined binding properties between Cx43 and CCN3 leading to an upregulation of CCN3 are needed for signaling. PMID: 20336664
CYR61 and NOV are regulated by HIF-1alpha and TGF-beta3 in the trophoblast cell line JEG3, and their enhanced secretion could be implicated in appropriate placental invasion. PMID: 20237132
CCN3 counter-regulates positive signals from TGF-beta and Wnt for fibrillin fibrillogenesis and profibrotic gene expression. PMID: 20182440
These findings identify a new paracrine role of NOV in the development of cerebellar granule neurons. PMID: 19286457
CCN3 suppresses neointimal thickening through the inhibition of vascular smooth cell migration and proliferation. PMID: 20139355
The angiogenic gene CCN3/nov was specifically downregulated in the plexiform neurofibromas and malignant peripheral nerve sheath tumor. PMID: 20010302
expression of this protein appears to be associated with a higher risk of developing metastases in Ewing's sarcoma PMID: 11891184
association with Notch1 extracellular domain and inhibition of myoblast differentiation via Notch signaling pathway PMID: 12050162
NOVH concentration was significantly modified in malignant but not benign adrenocortical tumors; the concentration of NOVH was significantly decreased in patients suffering from astrocytomas or multiple sclerosis PMID: 12519873
in endothelial cells, CCN3 supports cell adhesion, induces directed cell migration (chemotaxis), and promotes cell survival PMID: 12695522
NOVH increases cell adhesion and migration of glioblastoma cells via matrix metalloprotease 3 expression and a PDGFR-alpha dependent mechanism. PMID: 14519668
evidence that adenylate cyclase as well as one or several protein kinases might be involved in the mechanoregulation of Cyr61, CTGF and Nov genes PMID: 15053922
Cx43 is able to regulate cell growth via an up-regulation of NOV transcription PMID: 15181016
CCN3 has a role in cutaneous wound healing in skin fibroblasts PMID: 15611078
expression of CCN3 in Ewing's sarcoma primary tumors may be associated with a higher risk of developing lung and/or bone metastases PMID: 15824736
Data indicates that NOV is associated with carcinogenesis and the progression of renal cell carcinoma, and the NOV expression level is different in papillary-type and clear cell-type RCC. PMID: 16145471
Results suggest that NOV (nephroblastoma overexpressed) is a specific cell fate regulator in the myogenic lineage, acting negatively on key myogenic genes thus controlling the transition from progenitor cells to myoblasts. PMID: 16600215

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.